224 related articles for article (PubMed ID: 24053422)
1. Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer.
Hwang JE; Hong JY; Kim K; Kim SH; Choi WY; Kim MJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Lee KH; Lee JH; Cho SH; Chung IJ
BMC Cancer; 2013 Sep; 13():431. PubMed ID: 24053422
[TBL] [Abstract][Full Text] [Related]
2. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.
Koh Y; Kim TM; Jeon YK; Kwon TK; Hah JH; Lee SH; Kim DW; Wu HG; Rhee CS; Sung MW; Kim CW; Kim KH; Heo DS
Ann Oncol; 2009 Aug; 20(8):1414-9. PubMed ID: 19468031
[TBL] [Abstract][Full Text] [Related]
3. [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].
Huang J; Hu H; Xie Y; Tang Y; Liu W; Zhong M
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):582-9. PubMed ID: 23828702
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
5. Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S.
Di Bartolomeo M; Raimondi A; Cecchi F; Catenacci DVT; Schwartz S; Sellappan S; Tian Y; Miceli R; Pellegrinelli A; Giommoni E; Aitini E; Spada F; Rosati G; Marchet A; Pucci F; Zaniboni A; Tamberi S; Pressiani T; Sanna G; Cantore M; Mosconi S; Bolzoni P; Pinto C; Landi L; Soto Parra HJ; Cavanna L; Corallo S; Martinetti A; Hembrough TA; Pietrantonio F
Tumori; 2021 Apr; 107(2):150-159. PubMed ID: 32522106
[TBL] [Abstract][Full Text] [Related]
6. The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis.
Yang YL; Luo XP; Xian L
PLoS One; 2014; 9(4):e93997. PubMed ID: 24705847
[TBL] [Abstract][Full Text] [Related]
7. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
[TBL] [Abstract][Full Text] [Related]
8. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
Yu J; Gao J; Lu Z; Li Y; Shen L
Med Oncol; 2012 Dec; 29(5):3029-34. PubMed ID: 22766748
[TBL] [Abstract][Full Text] [Related]
10. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
Shi Y; Chen L; Li J; Lü YL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
[TBL] [Abstract][Full Text] [Related]
11. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
12. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
[TBL] [Abstract][Full Text] [Related]
13. Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer.
Yu J; Gao J; Lu Z; Gong J; Li Y; Dong B; Li Z; Zhang X; Shen L
Eur J Cancer; 2014 Sep; 50(13):2328-35. PubMed ID: 25016949
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
[TBL] [Abstract][Full Text] [Related]
15. The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy.
Kaira K; Takahashi T; Murakami H; Shukuya T; Kenmotsu H; Ono A; Naito T; Tsuya A; Nakamura Y; Endo M; Kondo H; Nakajima T; Yamamoto N
Int J Clin Oncol; 2013 Jun; 18(3):371-9. PubMed ID: 22358390
[TBL] [Abstract][Full Text] [Related]
16. Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors.
Kaira K; Serizawa M; Koh Y; Miura S; Kaira R; Abe M; Nakagawa K; Ohde Y; Okumura T; Naito T; Murakami H; Takahashi T; Kondo H; Nakajima T; Endo M; Yamamoto N
J Thorac Oncol; 2011 Mar; 6(3):606-13. PubMed ID: 21289518
[TBL] [Abstract][Full Text] [Related]
17. Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
Jeong SH; Han JH; Kim JH; Ahn MS; Hwang YH; Lee HW; Kang SY; Park JS; Choi JH; Lee KJ; Sheen SS; Lim HY
Dig Dis Sci; 2011 Jan; 56(1):131-8. PubMed ID: 20503071
[TBL] [Abstract][Full Text] [Related]
18. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
[TBL] [Abstract][Full Text] [Related]
19. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
Cancer Chemother Pharmacol; 2012 Nov; 70(5):743-54. PubMed ID: 22960937
[TBL] [Abstract][Full Text] [Related]
20. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
Jiang H; Wang H; Wang S; Pei Z; Fu Z; Fang C; Wang J; Lu Q; Wang E; Li J
Mol Med Rep; 2015 May; 11(5):3523-32. PubMed ID: 25573098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]